Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection.

CONCLUSION: Sofosbuvir and daclatasvir for treatment of KT recipients with HCV infection are highly efficient and safe. Patients tolerated the medications well, and no serious AEs were observed. Larger prospective cohort studies are needed to validate these results.
PMID: 28932089 [PubMed - in process]

Source: World Journal of Gastroenterology : WJG - August 28, 2017 Category: Gastroenterology Authors: Xue Y, Zhang LX, Wang L, Li T, Qu YD, Liu F Tags: World J Gastroenterol Source Type: research